Photo: Shifo Foundation

IA2030

WHO Member State Information Session

8 April 2021

Immunization Agenda 2030 -
A Global Strategy To Leave No One Behind

8 April 2021: Member State consultation

Session Outline

	Topic	Timing
1	**Welcome & Recap**	(10 mins)
2	**Overview** of IA2030 Framework for Action	(10 mins)
3	**IA2030 Launch**	(6 mins)
4	**Questions & Answers**	(60 mins)
5	**Next steps** and meeting close	(4 mins)

1 Welcome and Recap

IA2030 sets a unifying vision for the decade aligned with SDGs with clear impact goals

Vision

Impact goals

A world where everyone, everywhere, at every age...

Reduce mortality and morbidity from vaccine-preventable diseases for all across the life course.

...fully benefits from vaccines...

Leave no one behind, by increasing equitable access and use of new and existing vaccines.

**...for good health and well-being**

Ensure good health and well-being for everyone by strengthening immunization within primary health care and contributing to universal health coverage and sustainable development.

IA2030 proposes a strategic framework to achieve the vision and impact goals

7 Strategic Priorities

informed by

4 Core Principles for action

IA2030

August 2020 WHA 73 Resolution (9) – IA2030

...decided to endorse the new global vision and overarching strategy for vaccines and immunization: Immunization Agenda 2030 (IA2030)

The Director-General was also requested:

Focus of today

a) to **finalize the operational elements** outlined in the IA2030, in consultation with Member States and other relevant stakeholders **(by WHA 74 – May 2021);**

b) to **continue to monitor progress and to report biennially** as a substantive agenda item to the Health Assembly, through the Executive Board, on the achievements made in advancing towards the global goals of the IA2030 **(starting WHA 75 – May 2022)**

January 2021 EB 148/14 – IA2030

EB noted the report and took note of the progress made in advancing the implementation of the Immunization Agenda 2030 and provided guidance on the proposed frameworks for ownership and accountability, and for monitoring and evaluation.

Key IA2030 workstreams and timelines

Today

2020

2021

EB 73rd WHA

EB 74th WHA

Workstreams	2020	2021
IA2030 Vision & Strategy	• Endorsement at WHA	
Technical Annexes	• Content Development • Journal Supplement	
Online resources	• Online resources • Live	• Expanded website design
Comms & Advocacy	• Communication strategy • Launch	• Ongoing C&A
Regional plans	• Regional Implementation and Frameworks for Action	
Ownership & Accountability	• Design of O&A Framework	• Implementation
M&E Framework	• Design of M&E Framework	• Implementation

IA2030

IA2030: Focus has adapted to the context of COVID-19

Immediate priorities and challenges

- Global priority is rapid and equitable scale-up of COVID-19 vaccines

- Disruption and damage to immunization and other essential primary health care services

- Resources drawn away from existing vaccination activities

- Countries without vaccines targeting adults require tools, new approaches

- Increased risk of equity gaps

Adaptations in IA2030 opportunities and focus

- Immunization as a global priority

- Shorter-term planning to focus on recovery

- Collective action to rebuild essential services & systems, while reducing "zero-dose" children and communities

- An 'umbrella' partnership model building on multilateral collaboration and COVID-19 (e.g., COVAX, ACT-A)

- Life course approach and guidance

- Communication and advocacy messaging

- Strong case for role of vaccine deployment in economic recovery and global security

IA2030 Framework for Action

- What's New?
- Framework Overview
- Coordinated Operational Planning
- Monitoring & Evaluation
- Ownership & Accountability

IA2030

Key updates since last MS briefing and EB

Topic	What's new in the IA2030 Framework for Action?
COVID-19	• Critical focus on scale-up and recovery • Modified timeframes
Coordinated operational planning	• Initial planning with countries/regions, more realistic trajectories to 2030 post-COVID
Monitoring & Evaluation	• Updated Impact Goal indicators and targets • Updates to the M&E Framework (Annex 1)
Ownership & Accountability	• New presentation of global-level partnership model • New description of pledging process and tailored scorecards
Communications & Advocacy	• IA2030 website available • More information on launch and messaging • Request for Member State involvement and support in the launch

IA2030 Framework for Action

Vision
A world where everyone, at every age, fully benefits from vaccines for good health and well-being

Global Strategy
Including seven strategic priorities and technical annexes

Advises

Communication & Advocacy to stimulate and reinforce actions

4

1 **Planning for implementation**

supported by technical annexes

2 **Monitoring & Evaluation framework**

with action-based indicators

3 **Ownership & Accountability framework**

to drive commitments for action

Drives

Immunization Agenda 2030 Implementation Impact

IA2030 Vision and Strategy

Communications & Advocacy

1 Operational Planning

| National Immunization Strategies & plans | ⟷ | Regional Immunization Plans | ⟷ | Additional Global Strategies |

Additional Global Contributing Strategies:

SDGs
UHC 2030
GAVI 5.0
COVAX
Disease-specific initiatives
Partner Strategies

2 Monitoring & Evaluation

| Country M&E | ⟷ | Regional M&E | ⟷ | Global M&E |

M&E Tools:

Impact Goal Indicators

Strategic Priority Objective Indicators

Scorecards

3 Ownership & Accountability

| **Country O&A** Country-led mechanisms | ⟷ | **Regional O&A** Regional-led mechanisms | ⟷ | **Global O&A** A Partnership Council, Coordination Group & Consultation | ⟷ | **WHA** |

Independent Technical Review

| **Country** NITAG or equivalent | **Regional** RITAGs | **Global** SAGE |

O&A Tools:

Partner/ CSO Commitments

Public Pledges

Scorecards

4

IA2030

Regions adapt timelines and continue strategic planning for immunization during COVID-19 pandemic

WHO-AFRO example

Future deaths averted due to vaccination taking place each year from 2021-2030 in 194 Member States, if IA2030 coverage targets are achieved (globally average by year increase from 4.4-5.8m)

Step 1 - Currently in Progress Q1/Q2

✓ Discuss impact goals, objectives, and targets for 2030, and milestones (2025)

✓ Agree on regional strategy focus, consider uncertainities caused by COVID-19

Step 2 – Planning underway Q2

• Identify regional strategic priorities, key focus areas and indicators

• Conduct prioritisation exercise to focus on key accelerators

Steps 3 & 4 – Yet to advance in Q3/Q4

• Tailor operationalization (O&A, country support, communications and learning agenda)

• Finalise the development of regional strategy and launch the strategies

As regions recover, planning to take stock of new baselines and trajectory to 2030

13

IA2030 & Disease-Specific Initiatives
Identifying pathways to Integration

Integration Strategy

Member States called for integration

M&R Strategy designed as part of IA2030

GPEI Strategy integrated through shared focus on impact and action

IA2030

IA2030 Monitoring & Evaluation Framework Overview

IA2030 Goals and Objectives

3 Impact Goals

1 Reduce mortality and morbidity from vaccine-preventable diseases for everyone throughout the life course.

2 Leave no one behind, by increasing equitable access and use of new and existing vaccines.

3 Ensure good health and well-being for everyone by strengthening immunisation within primary health care and contributing to universal health coverage and sustainable development.

21 Strategic Priority Objectives

IA2030 Indicators

Impact Goal indicators:

7 indicators across global, regional, and country levels

Strategic Priority Objective indicators:

15 global indicators

Indicator options available for all 21 SP objectives for regions and countries to tailor M&E Frameworks based on context

IA2030 Impact Goal Indicators and Targets

Impact Goal	Indicator	2030 Target
1 Prevent Disease — Save lives	1.1 Number of future deaths averted through immunization[1]	**50 million future deaths averted globally**
Control, eliminate & eradicate VPDs	1.2 Number and % of countries achieving endorsed regional or global VPD control, elimination and eradication targets[2]	**All countries achieve the endorsed regional or global VPD control, eradication, and elimination targets**
Reduce VPD outbreaks	1.3 Number of large VPD outbreaks[3]	**50% reduction in number of large VPD outbreaks**
2 Promote Equity — Leave no one behind	2.1 Number of zero dose children	**50% reduction in the number of zero dose children at country, regional, and global levels**
Provide access to all vaccines	2.2 Introduction of new or under-utilized vaccines[4] in low and middle income countries	**TBD**
3 Build strong immunization programmes — Deliver across the life course	3.1 Vaccination coverage across the life course (DTP3, MCV2, HPVc, PCV3)[5]	**90% global coverage for DTP3, MCV2, HPVc, and PCV3**
Contribute to PHC/UHC	3.2 UHC Index of Service Coverage	**Improve UHC Index of Service Coverage at country, regional, and global levels**

1. Vaccine antigens included: HepB, Hib, HPV, JE, measles, MenA, Streptococcus pneumoniae, rotavirus, rubella, yellow fever, diphtheria, tetanus, pertussis, BCG. Measured relative to zero coverage levels (absence of vaccination); target includes deaths averted over the lifetime of the birth cohort by vaccines given during 2021-30.

2. Eradication (polio), elimination of transmission (measles, rubella), elimination as a public health problem (HPV, MNT, hepatitis B), control (Japanese encephalitis)

3. Large outbreaks of cholera, meningococcus, measles, polio, and yellow fever will be defined based on criteria for each disease. A 3-year mean will be used to account for year-to-year variation in outbreaks. The target will be achieved if the mean for 2028-2030 is at least 50% less than the baseline.

4. Vaccines include: HepB birth dose, HPV, IPV2, JE, YF, MCV2, meningococcus, PCV, rotavirus, rubella, DTP booster, COVID-19. Malaria and other new vaccines will potentially be included when recommended.

5. COVID-19 vaccination coverage will potentially be included.

IA2030

A partnership model at the global level builds on broad engagement

1

Consultative Engagement

*A process to strengthen the **"movement" of IA2030** –bringing in regions, countries, CSOs, donor voices to advise global partners on priorities and needed action.*

IA2030 Working Groups

- Strategic Priority (SP) technical working groups **at operational level** with representation across technical partners, including CSOs
- Other **cross-cutting thematic** working groups (e.g., Comms & Advocacy, Monitoring & Evaluation, Resource Mobilization)
- Meet regularly to discuss issues of relevance, technical alignment
- Organize consultative sessions with broad partner engagement (per above).

2

Coordination

IA2030 Coordination Group of core partners (Director level) meet monthly with timely follow-up, supported by small *Secretariat*

*The **operational driver** for global alignment and coordinated action.*

3

Leadership

IA2030 Partnership Council of 10-12 Senior leaders meet 1-2/year *(members include representation from country, regional and CSOs)*

*The **political leadership of IA2030,** providing the ownership and accountability at global levels*

IA2030

Reaching IA2030 targets will take resources

| ADVOCACY & POLITICAL WILL | TECHNICAL | FINANCIAL |

Consider 3 types of resources
Build on past experience and new partnerships
(e.g., GVAP, Gavi and COVAX)

- **Most resources are within Member States:** political will and alignment to reach IA2030 targets

- **IA2030 as an 'umbrella' for immunization:** including COVAX, Gavi, disease specific initiatives to strengthen alignment, efficiency & vaccine contribution to PHC, UHC & SDGs

- **Timing:** 2021-2023 > COVID equity related; 2023-2030 > longer term PHC related goals

- **Resources linked to needs:** use of tools (e.g., score cards) to strengthen accountability and ensure we reach communities most often left behind

- **Map resource gaps:** Prioritize technical and advocacy gaps first, then potential financial needs

IA2030

Designing tools to strengthen O&A and measure impact against IA2030 goals

| **1** **Partner pledging process**	**2** **Tailored scorecards**
To capture pledged commitments, ensure greater transparency, facilitate monitoring, and promote accountability	To measure progress as reported against IA2030 impact goals and strategic priority indicators and against pledged commitments
Initial process may engage development partners and CSOs at global levels	*Annually compiled from M&E framework (JRF reporting) and pledging process*

Communications & Advocacy

(4)

- IA2030 Launch
- Call for Member State participation
- IA2030 Website

Building momentum for IA2030: a rolling launch

World Immunization Week

March & April	April 26	June	Ongoing activations
Inform and engage the community	Galvanize energy and attention	Celebratory event after WHA	

Technical briefings

- Webinars with CSOs and technical partners to demystify IA2030 and showcase key strategic priorities

Global Press Launch

- Dr Tedros to introduce IA2030 at COVID press conference

- Media briefings and roundtables

- Amplify IA2030 messaging on social media, linking it to WIW

Celebratory Event after WHA

- Celebrate the new era and the launch of the partnership

- Showcase country & regional champions

- Share inspiring stories of what the IA2030 movement can achieve

- Launch a global call to action

Sustaining Momentum

- Targeted engagement at the country, regional and global level

- Building the movement for routine immunisation

Virtual Celebratory Event

Objective: Secure, amplify and celebrate tangible commitments to IA2030 and routine immunization

- High-level event to galvanise the community, celebrate the ambitions of this new era and launch the new Immunization Agenda Partnership Council (IAPC).

- Place a focus on country stories, national immunization champions, the power of consultative engagement and launching a country-led movement for routine immunization.

- Engage the community through a Global Call to Action

**Questions and support needed from the Core Partners:**
- Can you help us identify and secure IA2030 Champions?
- Can you share with us exceptional examples of what it means to maximise the impact of immunization and achieve the IA2030 ambitions?
- Continue to champion IA2030 internally in your organisations to help ensure IA2030 is embedded into your organisation's priorities for WHA planning, messaging and activities

The IA2030 Website is now available

www.immunizationagenda2030.org

Page contains all the key IA2030 documents:

- **IA2030 Vision and Strategy** in all six UN languages
- **Strategic Priority** technical annexes
- **Core Principle** annexes
- IA2030 **Framework for Action**
- Other IA2030 **annexes and companion** documents

5 Next Steps

Next Steps

1. **Today:** Information Session: MS Briefing (8 April)
2. **Feedback** to IA2030 Core Team **(by next Friday 16 April).**
   Please use email address: halena@who.int
3. Final version of Framework for Action available for WHA 74

Various timelines

Operational components and guidance

WHA 74 May 2021

IA2030
Vision and
Strategy

*Endorsed by WHA
in August 2020*

Country &
Regional Plans

SP and CP
Technical
Annexes

IA2030
Framework for
Action

WHA version

- *Oct 2020:* SAGE
- *Nov 2020:* Core Team alignment
- *Dec 2020:* MS Briefing
- *Jan 2021:* WHO Exec Board
- *Apr 2021*: MS Briefing and Core Team

IA2030
Framework for
Action
(final)

6 Comments, Questions & Answers

Back up Slide

IA2030 Global Strategic Priority Objective Indicators

IA2030

SP 1: Immunization Programmes for PHC/UHC

1.1 Proportion of countries with evidence of adopted mechanism for monitoring, evaluation and action at national and subnational levels

1.2 Density of physicians, nurses and midwives per 10,000 population

1.3 Proportion of countries with on-time reporting from 90% of districts for suspected cases of all priority VPDs included in nationwide surveillance

1.4 Proportion of time with full availability of DTPcv and MCV at service delivery level (mean across countries)

1.6 Proportion of countries with at least one documented individual serious AEFI case safety report per million total population

SP 2: Commitment & Demand

2.1 Proportion of countries with legislation in place that is supportive of immunization as a public good

2.2 Proportion of countries that have implemented behavioural or social strategies (i.e., demand generation strategies) to address under-vaccination

SP 3: Coverage & Equity

3.2 DTP3, MCV1, and MCV2 coverage in the 20% of districts with lowest coverage (mean across countries)

SP 4: Life course & Integration

4.1 Breadth of protection (mean coverage for all WHO-recommended vaccine antigens, by country)

SP 5: Outbreaks & Emergencies

5.1 Proportion of polio, measles, meningococcus, yellow fever, cholera, and Ebola outbreaks* with timely detection and response

SP 6: Supply & Sustainability

6.1 Level of health of the vaccine market, disaggregated by vaccine antigens and country typology**

6.2 Proportion of countries whose domestic government and donor expenditure on primary health care increased or remained stable

6.3 Proportion of countries whose share of national immunization schedule vaccine expenditure funded by domestic government resources increased

SP 7: Research & Innovation

7.1 Proportion of countries with an immunization research agenda

7.2 Progress towards global research and development targets***

includes only outbreaks with an outbreak response vaccination campaign

**following attributes will be measured: supply meeting demand; individual supplier risk; buffer capacity; long term competition*

****Targets will be set no later than 2022 and endorsed by SAGE*